Bicycle Therapeutics Stock Quote BCYC - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

20.11

Bid

20.02

Ask

20.22

Volume

14,126

20.00 Day's Range 20.71

0.00 52 Week Range 0.00

Market Cap

1.389B

Previous Close

20.36

Open

20.45

Last Trade

20.11

Last Trade Time

10:13:20

Financial Volume

$ 285,144

VWAP

20.1857

Average Volume (3m)

Shares Outstanding

69,046,021

Dividend Yield

PE Ratio

-7.66

Earnings Per Share (EPS)

-2.62

Revenue

26.98M

Net Profit

-180.66M

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused... Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.bicycletherapeutics.com

Headquarters

Cambridge, Gbr

Founded

Bicycle Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BCYC. The last closing price for Bicycle Therapeutics was $20.36. Over the last year, Bicycle Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Bicycle Therapeutics currently has 69,046,021 shares outstanding. The market capitalization of Bicycle Therapeutics is $1.41 billion. Bicycle Therapeutics has a price to earnings ratio (PE ratio) of -7.66.

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SKKSKK Holdings Limited	$ 10.86 (138.16%)	2.68M
WORXSCWorx Corporation	$ 2.15 (119.39%)	80.83M
CRNCCerence Inc	$ 4.50 (59.57%)	7.99M
SPAISafe Pro Group Inc	$ 4.3999 (37.50%)	34M
CDTConduit Pharmaceuticals Inc	$ 0.1243 (34.67%)	405.44M
PYXSPyxis Oncology Inc	$ 2.0101 (-47.38%)	6.59M
KURAKura Oncology Inc	$ 10.02 (-37.02%)	5.21M
BLRXBioLineRx Ltd	$ 0.3805 (-30.21%)	4.32M
AGFYAgrify Corporation	$ 27.2093 (-29.80%)	260.84k
SHOTWSafety Shot Inc	$ 0.11 (-26.67%)	1,000
CDTConduit Pharmaceuticals Inc	$ 0.1243 (34.67%)	405.44M
AKTSAkoustis Technologies Inc	$ 0.0995 (14.24%)	160.04M
NVDANVIDIA Corporation	$ 144.33 (-1.07%)	126.36M
WORXSCWorx Corporation	$ 2.15 (119.39%)	80.83M
ELABElevai Labs Inc	$ 0.02015 (-5.84%)	60.3M